Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$234.00K$234.00K−43.1% vs Q3 2024 Net Income-$14.09M-$14.09MN/M vs Q3 2024 EPS Diluted-$0.46-$0.46N/M vs Q3 2024 Operating Income-$15,120,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6461.5%−4543.3 pt vs Q3 2024
Net margin-6020.9%−4475.9 pt vs Q3 2024
ended Dec 31, 2024 · filed Feb 13, 2025 · 44 d after period end